Eyepoint Pharmaceuticals, Inc. $EYPT Holdings Trimmed by Blue Owl Capital Holdings LP

Key Points

• Blue Owl Capital cut its stake in Eyepoint Pharmaceuticals by 34.7% in Q3, selling 195,000 shares and retaining 367,594 shares (about $5.24M), making EYPT its 20th-largest holding.
• Eyepoint reported weak fundamentals recently — Q results showed a ($0.81) EPS miss versus ($0.78) expected and just $0.62M in revenue, with deeply negative margins and ROE.
• Analysts remain mostly positive overall: consensus is an average rating of “Buy” with a mean price target of $31.50, including several recent upgrades to strong-buy from firms like TD Cowen and Cantor Fitzgerald.

Blue Owl Capital Holdings LP reduced its position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 34.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 367,594 shares of the company's stock after selling 195,000 shares during the period. Eyepoint Pharmaceuticals makes up about 1.6% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 20th largest position. Blue Owl Capital Holdings LP owned approximately 0.44% of Eyepoint Pharmaceuticals worth $5,235,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Raymond James Financial Inc. boosted its position in shares of Eyepoint Pharmaceuticals by 11.0% during the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company's stock valued at $112,000 after purchasing an additional 1,177 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Eyepoint Pharmaceuticals by 17.3% in the 3rd quarter. New York State Common Retirement Fund now owns 12,214 shares of the company's stock worth $174,000 after purchasing an additional 1,800 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Eyepoint Pharmaceuticals by 1,636.5% during the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company's stock valued at $27,000 after purchasing an additional 2,733 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in Eyepoint Pharmaceuticals during the third quarter valued at approximately $50,000. Finally, Essex Investment Management Co. LLC boosted its holdings in Eyepoint Pharmaceuticals by 3.3% during the third quarter. Essex Investment Management Co. LLC now owns 127,789 shares of the company's stock worth $1,820,000 after buying an additional 4,098 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on EYPT. TD Cowen raised Eyepoint Pharmaceuticals to a "strong-buy" rating in a report on Friday, December 19th. Chardan Capital raised their price objective on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday. Weiss Ratings restated a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a "strong-buy" rating in a research report on Tuesday, November 25th. Finally, HC Wainwright increased their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $31.50.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT opened at $15.75 on Friday. The firm has a 50 day simple moving average of $15.66 and a 200 day simple moving average of $14.35. Eyepoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $19.11. The company has a market cap of $1.30 billion, a PE ratio of -4.98 and a beta of 1.72.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative return on equity of 93.46% and a negative net margin of 739.39%.The firm had revenue of $0.62 million for the quarter, compared to analysts' expectations of $1.01 million. On average, equities analysts predict that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Insider Activity at Eyepoint Pharmaceuticals

In other news, insider Ramiro Ribeiro sold 42,544 shares of the firm's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.46% of the stock is currently owned by company insiders.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.